Diagnostic Values of Serum Levels of Pepsinogens and Gastrin-17 for Screening Gastritis and Gastric Cancer in a High Risk Area in Northern Iran

  • Nejadi-Kelarijani, Fatemeh (Golestan Research Center of Gastroentrology and Hepatology, Golestan University of Medical Sciences) ;
  • Roshandel, Gholamreza (Golestan Research Center of Gastroentrology and Hepatology, Golestan University of Medical Sciences) ;
  • Semnani, Shahryar (Golestan Research Center of Gastroentrology and Hepatology, Golestan University of Medical Sciences) ;
  • Ahmadi, Ali (Department of Pathology, Tehran University of Medical Sciences) ;
  • Faghani, Behzad (Department of Pathology, Tehran University of Medical Sciences) ;
  • Besharat, Sima (Golestan Research Center of Gastroentrology and Hepatology, Golestan University of Medical Sciences) ;
  • Akhavan-Tabib, Atefeh (Golestan Research Center of Gastroentrology and Hepatology, Golestan University of Medical Sciences) ;
  • Amiriani, Taghi (Golestan Research Center of Gastroentrology and Hepatology, Golestan University of Medical Sciences)
  • Published : 2014.09.15


Background: Gastric cancer (GC) is the second cause of cancer related death in the world. It may develop by progression from its precancerous condition, called gastric atrophy (GA) due to gastritis. The aim of this study was to evaluate the accuracy of serum levels of pepsinogens (Pg) and gastrin-17 (G17) as non-invasive methods to discriminate GA or GC (GA/GC) patients. Materials and Methods: Subjects referred to gastrointestinal clinics of Golestan province of Iran during 2010 and 2011 were invited to participate. Serum levels of PgI, PgII and G17 were measured using a GastroPanel kit. Based on the pathological examination of endoscopic biopsy samples, subjects were classified into four groups: normal, non-atrophic gastritis, GA, and GC. Receiver operating curve (ROC) analysis was used to determine cut-off values. Indices of validity were calculated for serum markers. Results: Study groups were normal individuals (n=74), non-atrophic gastritis (n=90), GA (n=31) and GC patients (n=30). The best cut-off points for PgI, PgI/II ratio, G17 and HP were $80{\mu}g/L$, 10, 6 pmol/L, and 20 EIU, respectively. PgI could differentiate GA/GC with high accuracy (AUC=0.83; 95%CI: 0.76-0.89). The accuracy of a combination of PgI and PgI/II ratio for detecting GA/GC was also relatively high (AUC=0.78; 95%CI: 0.70-0.86). Conclusions: Our findings suggested PgI alone as well as a combination of PgI and PgI/II ratio are valid markers to differentiate GA/GC. Therefore, Pgs may be considered in conducting GC screening programs in high-risk areas.


Gastric cancer;pepsinogen;gastrin 17;early detection;screening programs


  1. Adamu MA, Weck MN, Rothenbacher D, Brenner H (2011). Incidence and risk factors for the development of chronic atrophic gastritis: five year follow-up of a population-based cohort study. Int J Cancer, 128, 1652-8.
  2. Cao Q, Ran ZH, Xiao SD (2007). Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin 17 and Helicobacter pylori immunoglobulin G antibodies. J Dig Dis, 8, 15-22.
  3. Copps J, Murphy RF, Lovas S (2009). The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers. Protein Pept Lett, 16, 1504.
  4. Correa P (1992). Human gastric carcinogenesis: a multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention. Cancer Res, 52, 6735-40.
  5. Dixon MF, Genta RM, Yardley JH, Correa P (1996). Classification and grading of gastritis. the updated sydney system. international workshop on the histopathology of gastritis, houston 1994. Am J Surg Pathol, 20, 1161-81.
  6. Ghasemi Kebria F, Bagheri H, Semnani S, Ghaemi E (2011). Seroprevalence of anti-Hp and anti-cagA antibodies among healthy persons in Golestan province, northeast of Iran (2010). Caspian J Intern Med, 2, 256-60.
  7. Iijima K, Abe Y, Kikuchi R, et al (2009). Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol, 15, 853-9.
  8. Kikuchi R, Abe Y, Iijima K, et al (2011). Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer. Tohoku J Exp Med, 223, 35-44.
  9. Kitahara F, Kobayashi K, Sato T, et al (1999). Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut, 44, 693-7.
  10. Lin SH, Li YH, Leung K, Huang CY, Wang XR (2014). Salt processed food and gastric cancer in a Chinese population. Asian Pac J Cancer Prev, 15, 5293-8.
  11. Lomba-Viana R, Dinis-Ribeiro M, Fonseca F, Vieira AS, et al (2012). Serum pepsinogen test for early detection of gastric cancer in a European country. Eur J Gastroenterol Hepatol, 24, 37-41.
  12. Mansour-Ghanaei F, Joukar F, Baghaei SM, et al (2012). Gastric precancerous lesions in first degree relatives of patients with known gastric cancer: a cross-sectional prospective study in Guilan Province, north of Iran. Asian Pac J Cancer Prev, 13, 1779-82.
  13. Miki K, Ichinose M, Ishikawa KB, et al (1993). Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res, 84, 1086-90.
  14. Miki K, Ichinose M, Shimizu A, et al (1987). Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn, 22, 133-41.
  15. Miki K, Morita M, Sasajima M, et al (2003). Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol, 98, 735-9.
  16. Nasrollahzadeh D, Aghcheli K, Sotoudeh M, et al (2011). Accuracy and cut-off values of pepsinogens i, ii and gastrin 17 for diagnosis of gastric fundic atrophy: influence of gastritis. PLoS One, 6, 26957.
  17. Oishi Y, Kiyohara Y, Kubo M, et al (2006). The serum pepsinogen test as a predictor of gastric cancer. Am J Epidemiol, 163, 629-37.
  18. Rollan A, Ferreccio C, Gederlini A, Serrano C, Torres J, Harris P (2006). Non-invasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. World J Gastroenterol, 12, 7172-8.
  19. Roshandel G, Sadjadi A, Aarabi M, et al (2012). Cancer Incidence in Golestan Province: Report of an Ongoing Population-based Cancer Registry in Iran between 2004 and 2008. Arch Iran Med, 15, 196-200.
  20. Shafaghi A, Mansour-Ghanaei F, Joukar F, et al (2013). Serum gastrin and the pepsinogen I/II ratio as markers for diagnosis of premalignant gastric lesions. Asian Pac J Cancer Prev, 14, 3931-6.
  21. Shikata K, Ninomiya T, Yonemoto K, et al (2012). Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scand J Gastroenterol, 47, 669-75.
  22. Shiotani A, Iishi H, Uedo N, et al (2005). Histologic and serum risk markers for noncardia early gastric cancer. Int J Cancer, 115, 463-9.
  23. Vannella L, Lahner E, Annibale B (2012). Risk for gastric neoplasias in patients with chronic atrophic gastritis: A critical reappraisal. World J Gastroenterol, 18, 1279-85.
  24. Watabe H, Mitsushima T, Yamaji Y, et al (2005). Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut, 54, 764-8.
  25. Yanaoka K, Oka M, Mukoubayashi C, et al (2008). Cancer highrisk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-aged males. Cancer Epidemiol Biomarkers Prev, 17, 838-45.
  26. Zheng RN, Li SR, Masahiro A (2012). Helicobacter pylori CagA and gastric carcinogenesis. Asian Pac J Cancer Prev, 13, 6305-10.
  27. Zhong C, Li KN, Bi JW, Wang BC (2012). Sodium intake, salt taste and gastric cancer risk according to Helicobacter pylori infection, smoking, histological type and tumor site in China. Asian Pac J Cancer Prev, 13, 2481-4.